1340 NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response

• Scott Daigle,
• David Ciccone,
• Samantha Carreiro,
• Christine Loh,
• Neelu Kaila,
• Fu-Shan Kuo,
• Scott Boiko,
• Gene Yau,
• Esha A Gangolli,
• Denise Levasseur,
• Bhaskar Srivastava,
• Frank G Basile

Affiliations

Scott Daigle

1Servier Pharmaceuticals, Boston, MA, United States

David Ciccone

1Nimbus Therapeutics, Cambridge, MA, USA

Samantha Carreiro

1Nimbus Therapeutics, Cambridge, MA, USA

Christine Loh

Nimbus Therapeutics, Boston, MA, USA

Neelu Kaila

1Nimbus Therapeutics, Cambridge, MA, USA

Fu-Shan Kuo

Nimbus Therapeutics, Boston, MA, USA

Scott Boiko

Nimbus Therapeutics, Boston, MA, USA

Gene Yau

Nimbus Therapeutics, Boston, MA, USA

Esha A Gangolli

Nimbus Therapeutics, Boston, MA, USA

Denise Levasseur

Nimbus Therapeutics, Boston, MA, USA

Bhaskar Srivastava

Nimbus Therapeutics, Boston, MA, USA

Frank G Basile

Nimbus Therapeutics, Boston, MA, USA